Literature DB >> 22581436

PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.

Terry W Moody1, Alessia Di Florio, Robert T Jensen.   

Abstract

The signal transduction mechanisms of pituitary adenylate cyclase activating polypeptide (PACAP) were investigated in lung cancer cells. Previously, PACAP-27 addition to NCI-H838 cells increased phosphatidylinositol turnover and intracellular cAMP leading to proliferation of lung cancer cells. Also, PACAP receptors (PAC1) regulated the tyrosine phosphorylation of ERK, focal adhesion kinase, and paxillin. In this communication, the effects of PACAP on cytosolic Ca(2+) and PYK-2 tyrosine phosphorylation were investigated. PACAP-27 increased cytosolic Ca(2+) within seconds after addition to FURA-2 AM loaded NCI-H838 cells. The increase in cytosolic Ca(2+) caused by PACAP was inhibited by PACAP(6-38) (PAC1 antagonist), U73122 (phospholipase C inhibitor), or BAPTA (calcium chelator), but not H89 (PKA inhibitor). PACAP-38, but not vasoactive intestinal peptide (VIP), addition to NCI-H838 or H1299 cells significantly increased the tyrosine phosphorylation of PYK-2 after 2 min. The increase in PYK-2 tyrosine phosphorylation caused by PACAP was inhibited by PACAP(6-38), U73122, or BAPTA, but not H89. The results suggest that PAC1 regulates PYK-2 tyrosine phosphorylation in a calcium-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581436      PMCID: PMC3419816          DOI: 10.1007/s12031-012-9785-6

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  35 in total

1.  Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.

Authors:  Terry W Moody; Nauramy Osefo; Bernardo Nuche-Berenguer; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2012-03-02       Impact factor: 4.030

Review 2.  Focal adhesion kinase: exploring Fak structure to gain insight into function.

Authors:  Jessica E Hall; Wei Fu; Michael D Schaller
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

3.  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.

Authors:  Ta-Jen Liu; Tiffany LaFortune; Toshiyuki Honda; Osamu Ohmori; Shinji Hatakeyama; Thomas Meyer; Dowdy Jackson; John de Groot; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

4.  Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.

Authors:  Terry W Moody; Julius Leyton; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2011-09-06       Impact factor: 3.444

Review 5.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

6.  Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.

Authors:  Siyang Zhang; Xueshan Qiu; Yumei Gu; Enhua Wang
Journal:  Lung Cancer       Date:  2008-06-20       Impact factor: 5.705

7.  Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Authors:  Jyotsnabaran Halder; Yvonne G Lin; William M Merritt; Whitney A Spannuth; Alpa M Nick; Toshiyuki Honda; Aparna A Kamat; Liz Y Han; Tae Jin Kim; Chunhua Lu; Ana M Tari; William Bornmann; Ariel Fernandez; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

8.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

Authors:  Walter Gregory Roberts; Ethan Ung; Pamela Whalen; Beth Cooper; Catherine Hulford; Christofer Autry; Daniel Richter; Earling Emerson; Jing Lin; John Kath; Kevin Coleman; Lili Yao; Luis Martinez-Alsina; Marianne Lorenzen; Martin Berliner; Michael Luzzio; Nandini Patel; Erika Schmitt; Susan LaGreca; Jitesh Jani; Matt Wessel; Eric Marr; Matt Griffor; Felix Vajdos
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

9.  Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Authors:  Kerby Shedden; Jeremy M G Taylor; Steven A Enkemann; Ming-Sound Tsao; Timothy J Yeatman; William L Gerald; Steven Eschrich; Igor Jurisica; Thomas J Giordano; David E Misek; Andrew C Chang; Chang Qi Zhu; Daniel Strumpf; Samir Hanash; Frances A Shepherd; Keyue Ding; Lesley Seymour; Katsuhiko Naoki; Nathan Pennell; Barbara Weir; Roel Verhaak; Christine Ladd-Acosta; Todd Golub; Michael Gruidl; Anupama Sharma; Janos Szoke; Maureen Zakowski; Valerie Rusch; Mark Kris; Agnes Viale; Noriko Motoi; William Travis; Barbara Conley; Venkatraman E Seshan; Matthew Meyerson; Rork Kuick; Kevin K Dobbin; Tracy Lively; James W Jacobson; David G Beer
Journal:  Nat Med       Date:  2008-07-20       Impact factor: 53.440

10.  Pituitary adenylate cyclase-activating polypeptide (PACAP)/PAC1HOP1 receptor activation coordinates multiple neurotrophic signaling pathways: Akt activation through phosphatidylinositol 3-kinase gamma and vesicle endocytosis for neuronal survival.

Authors:  Victor May; Eve Lutz; Christopher MacKenzie; Kristin C Schutz; Kate Dozark; Karen M Braas
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

View more
  3 in total

1.  Molecular mechanisms underlying the Nephroprotective effects of PACAP in diabetes.

Authors:  Eszter Banki; Krisztina Kovacs; Daniel Nagy; Tamas Juhasz; Peter Degrell; Katalin Csanaky; Peter Kiss; Gabor Jancso; Gabor Toth; Andrea Tamas; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2014-02-19       Impact factor: 3.444

Review 2.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

3.  Gene Expression Data Mining Reveals the Involvement of GPR55 and Its Endogenous Ligands in Immune Response, Cancer, and Differentiation.

Authors:  Artur Wnorowski; Jakub Wójcik; Maciej Maj
Journal:  Int J Mol Sci       Date:  2021-12-11       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.